Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3278370
Max Phase: Preclinical
Molecular Formula: C48H76N14O14
Molecular Weight: 1073.22
Molecule Type: Protein
Associated Items:
ID: ALA3278370
Max Phase: Preclinical
Molecular Formula: C48H76N14O14
Molecular Weight: 1073.22
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Standard InChI: InChI=1S/C48H76N14O14/c1-24(2)18-31(42(71)57-30(8-6-16-52-48(50)51)47(76)62-17-7-9-35(62)45(74)53-21-36(49)66)56-38(68)22-54-40(69)33(20-27-10-12-28(65)13-11-27)58-44(73)34(23-63)60-43(72)32(19-25(3)4)59-46(75)39(26(5)64)61-41(70)29-14-15-37(67)55-29/h10-13,24-26,29-35,39,63-65H,6-9,14-23H2,1-5H3,(H2,49,66)(H,53,74)(H,54,69)(H,55,67)(H,56,68)(H,57,71)(H,58,73)(H,59,75)(H,60,72)(H,61,70)(H4,50,51,52)/t26-,29+,30+,31+,32+,33+,34+,35+,39+/m1/s1
Standard InChI Key: RECYBHWCXXDEMO-IRZRDRLWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1073.22 | Molecular Weight (Monoisotopic): 1072.5665 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Humphries J, Wan YP, Folkers K.. (1977) Inhibition of the activity of the luteinizing hormone-releasing hormone (LH-RH) by analogues with variations at positions 2, 3, and 6 and the carboxyl terminus., 20 (7): [PMID:327068] [10.1021/jm00217a024] |
Source(1):